Abstract
Background. Recent data demonstrated that the −174 G > C IL-6 polymorphism may account for differences in the therapeutic response to laparoscopic adjustable gastric banding (LAGB) surgery. Objective. We investigated the impact of −174 G > C IL-6 polymorphism on weight loss, body composition, and fluid distribution changes in obese subjects after LAGB. Design and Outcome Measures. Twenty obese subjects were selected and studied at baseline and 3 months after LAGB. Genetic assessment of −174 G > C IL-6 polymorphism and anthropometric and bioelectrical impedance analysis were performed. Results. At baseline, C(+) carriers had a lower extracellular water (ECW) and higher intra-CW, phase angle (PA), reactance Xc, and Xc/height. LAGB surgery determined significant reductions in weight and BMI. After LAGB, in C(−) carriers, significant decreases in weight, BMI, and ECW and increases in BCM, BCMI, ICW, PA, and Xc/H were highlighted. In C(+) carriers, significant reductions in weight, BMI, ICW, and PA and increases in ECW, Na/K, resistance (R), and R/height were obtained. Significant higher reductions in BMI and Xc/H were observed in C(+) with respect to C(−) carriers. Conclusions. Genotyping of genetic variants, for example, the −174 G > C polymorphism of IL-6, gives the opportunity to predict therapeutic response, in terms of body composition outcomes after LAGB.
Highlights
Assessment of body composition plays an important role in clinical evaluation and in monitoring absolute and relative changes during specific therapeutic regimens in obese subjects [1]
We investigated the impact of −174 G > C IL6 polymorphism on weight loss, body composition, and fluid distribution changes in obese subjects after laparoscopic adjustable gastric banding (LAGB)
We recently provided evidence that the promoter polymorphism of IL-6 (−174 G > C) gene is associated both with body composition and fluid distribution, in obese subjects, at baseline and at 6-month follow-up after LAGB, suggesting that LAGB was less effective if the subjects were carrying risk genotypes (C-carriers) for obesity [10]
Summary
Assessment of body composition plays an important role in clinical evaluation and in monitoring absolute and relative changes during specific therapeutic regimens in obese subjects [1]. The weight losses induced by dietary or surgical treatment are more rapid in the first months and are associated with changes in body composition and fluid distribution [2]. Along with the increased acceptance of surgical procedures for weight loss in obesity, clinically useful baseline and follow-up measures of body composition and fluid distribution are critical to evaluate interventional outcomes. We investigated the impact of −174 G > C IL6 polymorphism on weight loss, body composition, and fluid distribution changes in obese subjects after LAGB. After LAGB, in C(−) carriers, significant decreases in weight, BMI, and ECW and increases in BCM, BCMI, ICW, PA, and Xc/H were highlighted. In C(+) carriers, significant reductions in weight, BMI, ICW, and PA and increases in ECW, Na/K, resistance (R), and R/height were obtained. Genotyping of genetic variants, for example, the −174 G > C polymorphism of IL-6, gives the opportunity to predict therapeutic response, in terms of body composition outcomes after LAGB
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have